ערך בספרים למניה: Revance Therapeutics, Inc. (RVNC)

Revance Therapeutics growth is based on the long-lasting effect of Daxxify and expansion into spasticity therapy. The book value per common share on the chart confirms that this metric equals -1.54. High precision is achieved through automated filling lines. However, aggressive marketing of new injections is causing a cash deficit, resulting in operating expenses temporarily exceeding current revenue.

For Revance Therapeutics (RVNC), whose aesthetic dermatology revenues are subject to strong seasonality and macroeconomic volatility, this indicator serves as a measure of financial resilience during periods of declining demand. The book value per share is calculated as the difference between all company assets and liabilities divided by the number of shares, reflecting the real value of net assets for the investor.